Ann C Vorwald

US Patent:

6641819, Nov 4, 2003

Filed:

Oct 18, 2001

Appl. No.:

09/981282

Inventors:

William L. Mengeling - Ames IA
Ann Vorwald - Ames IA
Kelly Lager - Neveda IA
Kelly Burkhart - Radcliffe IA
David E. Gorcyca - St. Joseph MO
Mike Roof - Ames IA

Assignee:

USDA - Peoria IL
Boehringer Ingelheim Corp. - Ridgefield CT

International Classification:

A61K 3912

US Classification:

4242041, 4241841, 424815, 435 691, 435 6, 4352351

Abstract:

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.

US Patent:

6660513, Dec 9, 2003

Filed:

May 9, 2002

Appl. No.:

10/143186

Inventors:

William L. Mengeling - Ames IA
Ann Vorwald - Ames IA
Kelly Lager - Neveda IA
Mike Roof - Ames IA
Kelly Burkhart - Radcliffe IA
David E. Gorcyca - St. Joseph MO

Assignee:

USDA - Peoria IL
Boehringer Ingelheim Corp. - Ridgefield CT

International Classification:

C12N 700

US Classification:

4352351, 435325, 435239, 435 6

Abstract:

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation.

US Patent:

7081342, Jul 25, 2006

Filed:

Sep 3, 2003

Appl. No.:

10/654545

Inventors:

William L. Mengeling - Ames IA, US
Ann Vorwald - Ames IA, US
Kelly Lager - Neveda IA, US
Kelly Burkhart - Radcliffe IA, US
David E. Gorcyca - St. Joseph MO, US
Mike Roof - Ames IA, US

Assignee:

Boehringer Ingelheim Vetmedica, Inc. - St. Joseph MO

International Classification:

C12Q 1/68

US Classification:

435 6, 435 691, 435 912

Abstract:

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.

US Patent:

8491916, Jul 23, 2013

Filed:

Jul 24, 2006

Appl. No.:

11/459542

Inventors:

William L. Mengeling - Ames IA, US
Ann Vorwald - Ames IA, US
Kelly Lager - Neveda IA, US
Mike Roof - Ames IA, US
Kelly Burkhart - Radcliffe IA, US
David E. Gorcyca - St. Joseph MO, US

Assignee:

The United States of America as represented by the Secretary of Agriculture - Washington DC
Boehringer Ingelheim Vetmedica, Inc. - St. Joseph MO

International Classification:

A61K 39/12
C07H 21/04
C12N 7/00
C12N 15/86

US Classification:

4242041, 435456, 4352351, 536 2372

Abstract:

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.

US Patent:

20110104201, May 5, 2011

Filed:

Feb 20, 2009

Appl. No.:

12/389558

Inventors:

William L. Mengeling - Ames IA, US
Ann Vorwald - Ames IA, US
Kelly Lager - Neveda IA, US
Mike Roof - Ames IA, US
Kelly Burkhart - Radcliffe IA, US
David E. Gorcyca - St. Joseph MO, US

International Classification:

A61K 39/12
C07H 21/04
C12N 7/00
A61P 37/02
A61P 31/12

US Classification:

4242041, 536 2372, 4352351

Abstract:

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.

US Patent:

59765372, Nov 2, 1999

Filed:

Jul 2, 1996

Appl. No.:

8/674475

Inventors:

William L. Mengeling - Ames IA
Kelly M. Lager - Nevada IA
Ann C. Vorwald - Ames IA

Assignee:

The United States of America as represented by the Secretary of
Agriculture - Washington DC

International Classification:

A61K 3900
A61K 3912
C12N 708

US Classification:

4241841

Abstract:

Vaccines against porcine reproductive and respiratory syndrome (PRRS) have been produced by attenuation of wild type strains of the virus selected from the group of attenuated NADC-8, attenuated NADC-9 and attenuated NVSL-14. These vaccines are useful in monovalent, bivalent or polyvalent vaccines.

US Patent:

60156635, Jan 18, 2000

Filed:

Mar 1, 1996

Appl. No.:

8/609334

Inventors:

Ronald D. Wesley - Ames IA
Deborah F. Clouser - Ames IA
William L. Mengeling - Ames IA
Vladimir G. Andreyev - Vladimir, RU
Ann C. Vorwald - Ames IA
Kelly M. Lager - Nevada IA

Assignee:

The United States of America as represented by the Secretary of
Agriculture - Washington DC

International Classification:

C12Q 170
C12Q 168

US Classification:

435 5

Abstract:

A test based on restriction enzyme analysis identifies and differentiates strains of porcine reproductive and respiratory syndrome virus (PRRSV). Amplified cDNA from the ORF 5 region of the viral genome has been targeted for identification of unique restriction sites that allow for the differentiation of the vaccine strain from field strains, and for differentiation of field strains from each other through the use of selected restriction enzymes. This assay is useful for both clinical diagnosis of PRRSV field strains in vaccinated pigs as well as for epidemiological studies in the evaluation of the source and transmission of PRRS field viruses.